1,4-二氢-2,6-二甲基-4-(3'-硝基苯基)-吡啶-3,5-二羧酸 | 74936-81-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1,4-二氢-2,6-二甲基-4-(3'-硝基苯基)-吡啶-3,5-二羧酸
• 中文别名: 贝尼地平杂质E
• 英文名称: 1,4-dihydro-2,6-dimethyl-4-(3'-nitrophenyl)-pyridine-3,5-dicarboxylic acid
• 英文别名: 2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid；1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid；2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid
• CAS: 74936-81-5
• 化学式: C₁₅H₁₄N₂O₆
• 分子量: 318.286
• InChiKey: TZDPJNSHSWMCPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1,4-二氢-2,6-二甲基-4-(3'-硝基苯基)-吡啶-3,5-二羧酸 在 lipase AH 、 水 、 sodium hydride 作用下， 以 异丙醚 为溶剂， 反应 53.5h， 生成 (S)-(+)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-pivaloyloxymethoxycarbonyl-3-pyridinecarboxylic acid
  参考文献：
  名称：

  Lipase-Catalyzed Enantioselective Hydrolysis of Bis(acyloxymethyl) 1,4-Dihydro-3,5-pyridinedicarboxylates Leading to Optically Active Medicines.

  摘要：

  手性4-芳基-1, 4-二氢-2, 6-二甲基-3, 5-吡啶二甲酸酯和1, 4-二氢-2, 4, 6-三甲基-3, 5-吡啶二甲酸酯的产率为80-99% ee 通过在 H2O/有机溶剂系统中脂肪酶催化双(酰氧基甲基) 1, 4-二氢-3, 5-吡啶二甲酸酯的水解得到。这些手性二氢吡啶很容易转化为手性药物，如尼卡地平、非洛地平和 PCA 4248。

  DOI：

  10.1248/cpb.45.863
• 作为产物：
  描述：

  间-硝苯地平 生成 1,4-二氢-2,6-二甲基-4-(3'-硝基苯基)-吡啶-3,5-二羧酸
  参考文献：
  名称：

  WILSON, ALAN A.;DANNALS, ROBERT F.;RAVERT, HAYDEN T.;BURNS, H. DONALD;LEV+, J. LABELL. COMPOUNDS AND RADIOPHARM., 27,(1989) N, C. 589-598

  摘要：

  DOI：

文献信息

• 1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof
  申请人：Zhang Hui

  公开号：US20140045896A1

  公开（公告）日：2014-02-13

  The present invention relates to a 1,4-dihydropyridine-3,5-dicarboxylate compound of general compound (I), a process for preparing the same, a use thereof for the manufacture of a medicament for treating and/or preventing kidney injury, cardiovascular diseases and/or endocrine diseases, as well as a pharmaceutical composition and a pharmaceutical formulation containing said compounds, wherein the definitions of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , m, n 1 , n 2 , p and q are the same as those defined in the description.

  本发明涉及一种一般化合物(I)的1,4-二氢吡啶-3,5-二羧酸酯化合物，以及其制备方法，用于制备治疗和/或预防肾脏损伤、心血管疾病和/或内分泌疾病的药物的用途，以及含有所述化合物的药物组合物和制剂，其中R1、R2、R3、R4、R5、R6、R7、R8、m、n1、n2、p和q的定义与描述中定义的相同。
• Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions
  申请人：Jobdevairakkam Christopher N.

  公开号：US20080125595A1

  公开（公告）日：2008-05-29

  A process of preparing a stable parenteral solution of a 1,4-dihydropyridine salt, such as nicardipine hydrochloride, in an acidic aqueous medium. The presence of L-arginine in the solution enhances the solubility of the salt, which is poorly soluble in water. An aqueous, injectable isotonic solution at pH about 3.5-3.6 consists essentially of nicardipine hydrochloride, L-arginine, and a sugar alcohol. An improved single pot manufacturing process for obtaining unsymmetrical 1,4-dihydropyridines by using more than one mole equivalent of aldehyde with respect to the other reactants (amino crotonate and acetoacetate ester). The reaction can be conducted in a solvent present at 20 times the amount of any one component. A process for changing one polymorph of nicardipine hydrochloride (Form A) into another (Form B), and a separate process for the reverse (Form B into Form A).

  一种制备1,4-二氢吡啶盐（如盐酸尼卡地平）的稳定无菌溶液的工艺，该工艺在酸性水介质中进行。溶液中存在L-精氨酸，可增强盐的溶解度，而盐在水中溶解度较差。该无菌溶液为水溶性、注射用的等渗溶液，pH值约为3.5-3.6，主要由盐酸尼卡地平、L-精氨酸和糖醇组成。 一种改进的单锅制造工艺，用于通过使用超过其他反应物（氨基丙烯酸酯和乙酰乙酸酯）的摩尔当量的醛类来获得非对称的1,4-二氢吡啶。该反应可以在溶剂中进行，溶剂的量为任何一个组分的20倍。 一种将尼卡地平盐酸的一种多晶形式（A型）转变为另一种多晶形式（B型）的工艺，以及将B型转变为A型的单独工艺。
• 1,4-dihydropyridine derivatives
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US04948899A1

  公开（公告）日：1990-08-14

  A 1,4-dihydropyridine derivative represented by the formula ##STR1## wherein R.sup.1 is a hydrogen atom, an alkoxy group having 1 to 4 carbon atoms, a mercapto group, an alkylcarbonylthio group in which the alkyl group has 1 to 4 carbon atoms or a benzoylthio group, R.sup.2 is a mercapto group, an alkylcarbonylthio group in which the alkyl group has 1 to 4 carbon atoms, a benzoylthio group or a 2-cyanoethylthio group, A and B are the same or different and are each an alkylene group having 1 to 4 carbon atoms, and X is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group is disclosed. These compounds increase the therapeutic effect of drug-resistant cancers.

  公开了一种由以下式子表示的1,4-二氢吡啶衍生物：##STR1## 其中，R.sup.1是氢原子，具有1至4个碳原子的烷氧基，巯基，烷基羰基硫基，其中烷基具有1至4个碳原子，或苯甲酰硫基；R.sup.2是巯基，烷基羰基硫基，其中烷基具有1至4个碳原子，苯甲酰硫基或2-氰基乙基硫基；A和B相同或不同，分别是具有1至4个碳原子的亚烷基基团；X是氢原子，卤素原子，硝基或三氟甲基基团。这些化合物增强了耐药癌症的治疗效果。
• 1,4-Dihydropyridine derivatives and use as vasodilators
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US04472411A1

  公开（公告）日：1984-09-18

  The compounds of the formula ##STR1## wherein R is alkyl having 1 to 4 carbon atoms or nitratoalkyl having 2 or 3 carbon atoms, and R' is nitratoalkyl having 2 or 3 carbon atoms, are disclosed. These compounds are useful as therapeutic agents for cardiovascular disorders such as coronary artery disease, cerebral artery disease, hypertension and the like.

  本发明揭示了具有以下公式的化合物##STR1##其中R是1到4个碳原子的烷基或2或3个碳原子的硝基烷基，R'是2或3个碳原子的硝基烷基。这些化合物可用作治疗心血管疾病，如冠状动脉疾病，脑动脉疾病，高血压等的治疗剂。
• Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
  申请人：Mullan J. Michael

  公开号：US20060188938A1

  公开（公告）日：2006-08-24

  Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.

  提供了对治疗与阿尔茨海默病相关的脑部淀粉样蛋白沉积疾病（如阿尔茨海默病）有用的化合物。还提供了筛选此类化合物的方法，通过测量细胞中的电容性钙离子入流，该细胞可选择过表达APP或其片段。还提供了通过给予治疗有效量的化合物来治疗或降低β-淀粉样蛋白产生、β-淀粉样蛋白沉积、β-淀粉样蛋白神经毒性（包括tau异常的超磷酸化）和与阿尔茨海默病相关的微胶质细胞病的风险的方法，这些化合物降低细胞中的β-淀粉样蛋白产生和电容性钙离子入流。此外，还提供了通过给予诊断有效量的化合物来诊断动物或人类中与阿尔茨海默病相关的脑部淀粉样蛋白沉积疾病的方法，这些化合物抑制细胞中的电容性钙离子入流。